创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

YANG Yuejing, TU Zhenlin, TANG Weifang, CHEN Yadong. Research Progress of Wee1 Kinase and Its Inhibitors[J]. Progress in Pharmaceutical Sciences, 2022, 46(1): 71-80.
Citation: YANG Yuejing, TU Zhenlin, TANG Weifang, CHEN Yadong. Research Progress of Wee1 Kinase and Its Inhibitors[J]. Progress in Pharmaceutical Sciences, 2022, 46(1): 71-80.

Research Progress of Wee1 Kinase and Its Inhibitors

  • Mitosis is completed under the precise control of cell cycle, which relies on the checkpoints of G1/S phase, S phase and G2/M phase to block the division process in time to ensure the integrity of genetic information. Since most human tumor cells have p53 mutations and p53 functional defects, the G1/S phase checkpoints are inactivated, leading to higher dependence on the regulation of G2/M checkpoints. The cell cycle regulatory protein Wee1 kinase is a key regulator of the G2/M checkpoint. It achieves G2/M phase blocked by phosphorylation of CDK1 Tyr15, which provides time for DNA repair. Inhibition of Wee1 can eliminate cell cycle block, make tumor cells enter mitosis prematurely, and produce replication stress and mitotic disaster. Wee1 is highly expressed in many tumors, so it is an ideal target for the treatment of tumors, with its inhibitors becoming a hot research topic. This article mainly introduces the mechanism of Wee1 kinase, its relevance to diseases, and the clinical application of small molecule inhibitors under investigation, in order to provide ideas for its further research and application.
  • loading

Catalog

    Turn off MathJax
    Article Contents

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return